Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China flag China · Delayed Price · Currency is CNY
255.06
-3.44 (-1.33%)
At close: Mar 9, 2026

SHA:688506 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
105,308133,40076,88456,100--
Upgrade
Market Cap Growth
47.15%73.51%37.05%---
Upgrade
Enterprise Value
102,921131,01373,45856,019--
Upgrade
Last Close Price
255.06323.10191.73139.90--
Upgrade
PE Ratio
--20.74---
Upgrade
Forward PE
--71.91---
Upgrade
PS Ratio
41.7952.9313.2099.85--
Upgrade
PB Ratio
14.6918.6019.79369.39--
Upgrade
P/TBV Ratio
14.7518.6819.92452.87--
Upgrade
P/FCF Ratio
--19.34---
Upgrade
P/OCF Ratio
--18.94---
Upgrade
EV/Sales Ratio
40.8451.9912.6299.70--
Upgrade
EV/EBITDA Ratio
--19.57---
Upgrade
EV/EBIT Ratio
--19.93---
Upgrade
EV/FCF Ratio
--18.48---
Upgrade
Debt / Equity Ratio
0.530.530.534.530.590.87
Upgrade
Debt / EBITDA Ratio
--0.55---
Upgrade
Debt / FCF Ratio
--0.52---
Upgrade
Net Debt / Equity Ratio
-0.33-0.33-0.951.87-0.490.40
Upgrade
Net Debt / EBITDA Ratio
3.673.67-0.98-0.391.68-1.21
Upgrade
Net Debt / FCF Ratio
---0.93-0.411.56-0.74
Upgrade
Asset Turnover
--1.360.330.480.80
Upgrade
Inventory Turnover
--1.872.002.592.75
Upgrade
Quick Ratio
--2.990.521.730.62
Upgrade
Current Ratio
--3.190.741.940.90
Upgrade
Return on Equity (ROE)
-19.00%-19.00%183.64%-143.77%-44.62%-25.51%
Upgrade
Return on Assets (ROA)
--53.82%-28.74%-14.01%-10.00%
Upgrade
Return on Invested Capital (ROIC)
-15.01%-28.80%1077.87%-172.17%-70.10%-38.81%
Upgrade
Return on Capital Employed (ROCE)
--71.50%-211.60%-26.30%-33.20%
Upgrade
Earnings Yield
-1.00%-0.79%4.82%-1.39%--
Upgrade
FCF Yield
--5.17%-1.24%--
Upgrade
Payout Ratio
--1.03%---
Upgrade
Buyback Yield / Dilution
-3.20%-3.20%-0.14%-10.56%-1.38%-3.64%
Upgrade
Total Shareholder Return
-3.20%-3.20%-0.14%-10.56%-1.38%-3.64%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.